Skip to main content

Advertisement

SpringerLink
Log in

The value of innovation: the economics of targeted drugs for cancer

  • Perspectives
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Oncology therapeutics have entered a new era, with the recent approval by the US Food and Drug Administration of 16 novel targeted agents. In many instances, these agents have led to breakthroughs in cancer care, such as imatinib for the treatment of chronic myeloid leukemia and bevacizumab for the treatment of colorectal, lung, and breast cancers. Toxicities of targeted agents are also novel-no longer primarily resulting in hematologic, gastrointestinal, and skin toxicities. As with all new and innovative therapies, the price tags for these agents are substantial, ranging from a mean per person annual cost of $13,000 to $100,000 in many cases. Despite the high cost of these drugs, the value of these agents has been important. In this paper, we review the concepts of value and cost effectiveness as they apply to targeted cancer agents and provide some initial insights on the economics of targeted oncology drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berenson A (2006) A cancer drug shows promise, at a price that many can’t pay. In: New York Times. http://www.nytimes.com/2006/02/15/business/15drug.html?ei=5090&en=62aabaec5acffa8. Accessed 7 Dec 2006

  2. Schulman KA, Glick HA, Yabroff R, Eisenberg JM (1995) Introduction to clinical economics: assessment of cancer therapies. J Natl Cancer Inst Monographs 9:1–9

    Google Scholar 

  3. Cohen S (2004) Benefits of extending medicare coverage to all oral anti-cancer drugs. J Undergrad Res 5(6)

  4. Bicknell R (2005) The realisation of targeted antitumour therapy. Br J Cancer 92(Suppl 1):S2–S5

    Article  PubMed  CAS  Google Scholar 

  5. Segota E, Bukowski RM (2004) The promise of targeted therapy: cancer drugs become more specific. Clevel Clin J Med 71(7):551–560

    Article  Google Scholar 

  6. Culliton B (2006) Science for life: a conversation with Nobel Laureate David Baltimore. Health Affairs - Web Exclusive, 16 May:w235–w240

  7. Andersen MR et al (2004) Examining the cost-effectiveness of cancer screening promotion. Cancer 101(Suppl 5):1229–1238

    Article  PubMed  Google Scholar 

  8. Schrag D (2004) The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 351(4):317–319

    Article  PubMed  CAS  Google Scholar 

  9. Klepper B, Pauker D (2006) Medicare’s drug plan: huge price disparities for common cancer drugs. Community Oncology 3(12):753–755

    Google Scholar 

  10. Bowman J, Rousseau A, Silk D, Harrison C (2006) Access to cancer drugs in medicare part D: formulary placement and beneficiary cost sharing in 2006. Health Aff 25(5):1240–1248

    Article  Google Scholar 

  11. National Cancer Institute, US National Institutes of Health (2006) Dictionary of Cancer Terms. http://www.cancer.gov/Templates/db_alpha.aspx?print=1&cdrid=270742. Accessed 11 Dec 2006

  12. Kaiser Family Foundation (2006) New York Times Examines Concerns Over High Cost of Cancer Medication Avastin. In: Kaisernetwork.org. Daily Health Policy Report - Prescription Drugs. http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=3&DR_ID=35433. Accessed 13 Dec 2006

  13. Meropol NJ, Schulman KA (2007) Cost of cancer care: issues and implications. J Clin Oncol 25(2):180–186

    Article  PubMed  Google Scholar 

  14. Herper M (2004) Cancer’s Cost Crisis. In: Forbes.com. http://www.forbes.com/technology/2004/06/08/cx_mh_0608costs.html. Accessed 7 Feb 2007

  15. Yabroff KR et al (2007) Patient time costs associated with cancer care. J Natl Cancer Inst 99(1):14–23

    Article  PubMed  Google Scholar 

  16. Di Masi J, Grabowski HG (2007) Economics of new oncology drug development. J Clin Oncol 25(2):209–216

    Article  Google Scholar 

  17. Graham JD et al (1998) Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 19:125–152

    Article  PubMed  CAS  Google Scholar 

  18. Avastin package insert. FDA Website. http://www.fda.gov/cder/foi/label/2006/125085s085lbl.pdf

  19. Campath Package Insert. FDA Website. http://www.fda.gov/cder/foi/label/2006/103948s5065lbl.pdf

  20. Erbitux package insert. FDA Website. http://www.fda.gov/cder/foi/label/2006/125084s046LBL.pdf

  21. Herceptin package insert. FDA Website. http://www.fda.gov/cder/foi/label/2006/103792s5150lbl.pdf

  22. Bexxar package insert. FDA Website. http://www.fda.gov/cder/foi/label/2004/125011_0024lbl.pdf

  23. Rituxan package insert. Genentech website. http://www.gene.com/gene/products/information/pdf/rituxan_prescribing.pdf

  24. Mylotarg package insert. FDA Website. http://www.fda.gov/cder/foi/label/2006/021174s020lbl.pdf

  25. Zevalin package insert. FDA Website. http://www.fda.gov/cder/foi/label/2005/125019_0092lbl.pdf

  26. Vectibix package insert. Amgen Website. http://wwwext.amgen.com/pdfs/products/vectibix_pi.pdf

  27. Gleevec package insert. Novartis Website. http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf

  28. Iressa package insert. AstraZeneca Website. http://www.astrazeneca_us.com/pi/iressa.pdf

  29. Tarceva package insert. FDA Website. http://www.fda.gov/cder/foi/label/2005/021743s003lbl.pdf

  30. Velcade package insert. FDA Website. http://www.fda.gov/cder/foi/label/2006/021602s010lbl.pdf

  31. Nexavar package insert. http://www.fda.gov/cder/foi/label/2005/021923lbl.pdf

  32. Sutent package insert. http://www.pfizer.com/pfizer/download/uspi_sutent.pdf

  33. Sprycel package insert. http://www.bms.com/cgi_bin/anybin.pl?sql=select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=113&key=PPI

  34. Mann B (2004) Triumph of Hope Over Reason. http://www.fool.com/investing/small_cap/2004/09/01/triumph_of_hope_over_reason.aspx Accessed 18 Jan 2007

  35. Fierce Biotech (2006) Amgen launches price war on Vectibix OK. In: Drug Discovery, Sept 28. http://www.fiercebiotech.com/story/amgen_launches_price_war_on_vectibix_ok/2006_09_28. Accessed 18 Jan 2007

  36. Genzyme g_Care Newsletter Volume 7 (2005) http://www.genzymegenetics.com/pdf/gene_p_payors_newsletter%209_03.pdf Accessed 18 Jan 2007

  37. Gallagher T (2007) http://cogentpassion.blogspot.com/2006/06/i_bought_onxx_onyx_pharm.html Accessed 18 Jan 2007

  38. Pharma Times (2006) B-MS wins US OK for leukaemia drug Sprycel. In: World News, June 30. http://www.pharmatimes.com/WorldNews/Articles/9141_BMS_Sprycel.aspx?src=PTNews_10049 Accessed 18 Jan 2007

  39. US Department of Health and Human Services (2004) Medicare to Extend Access to Certain Drugs for Beneficiaries with Serious and Chronic Illnesses. http://www.dhhs.gov/news/press/2004pres/20040624.html Accessed 18 Jan 2007

  40. American Cancer Society (2005) A Better Drug for Relapsed Multiple Myeloma. http://www.cancer.org/docroot/NWS/content/NWS_1_1x_A_Better_Drug_for_Relapsed_Multiple_Myeloma.asp Accessed 18 Jan 2007

  41. Biopeer (2006) FDA approves Pfizer’s new cancer drug. http://www.biopeer.com/biopeer/2006/01/fda_approves_pf.html Accessed 18 Jan 2007

  42. Berenson A (2005) Cancer Drugs Offer Hope, but at a Huge Expense. In: New York Times, July 12. http://www.nytimes.com/2005/07/12/business/12cancer.html?ex=1278820800&en=1eb889752ca5eb49&ei=5088 Accessed 18 Jan 2007

  43. Medical News Today (2006) UK Court Decides Health Trust Cannot Cherry Pick Herceptin Users. http://www.medicalnewstoday.com/healthnews.php?newsid=41514 Accessed 18 Jan 2007

  44. Tortora A (2002) The Cure and the Cost: Medical breakthroughs promise to save lives. Can we afford them? In: Cincinnati Business Courier, June 14. http://cincinnati.bizjournals.com/cincinnati/stories/2002/06/17/story3.html Accessed 18 Jan 2007

  45. Timmerman L (2003) Corixa wins full reimbursement for lymphoma drug. In: The Seattle Times. http://archives.seattletimes.nwsource.com/cgi_bin/texis.cgi/web/vortex/display?slug=corixa12&date=20030912 Accessed 18 Jan 2007

  46. Patel J (2006) Korean A-7 Prices Compared to U.S. Prices. In: Drug Development, July 31. http://www.cptech.org/blogs/drugdevelopment/2006/07/korean_7_prices_compared_to_us_prices_31.html Accessed 18 Jan 2007

  47. Pringle E (2006) Genentech and Biogen Legal Troubles-When It Rains It Pours. http://www.lawyersandsettlements.com/articles/rituxan.html Accessed 18 Jan 2007

  48. Tamir O, Rabinovich M, Shani M (2006) Year 2006 Update of the Israel National List of Health Services. http://www.ima.org.il/imaj/ar06sep_1.pdf Accessed 18 Jan 2007. IMAJ 8:595_600

  49. NCD for Anti-Cancer Chemotherapy for Colorectal Cancer (110.17). Publication Number 12-3. Medicare Coverage Database. Centers for Medicare & Medicaid Services, U.S. Department of Health & Human Services. Available at http://www.cms.hhs.gov/mcd/viewncd.asp?ncd_id=110.17&ncd_version=1&basket=ncd. Accessed 4 Jan 2007

  50. Clinical Coverage Criteria. Tufts Health Plan may authorize coverage of Tarceva- and Iressa. Available at: http://www.tuftshealthplan.com/providers/pdf/pharmacy_criteria/Iressa.pdf. Accessed 8 Jan 2007

Download references

Author information

Authors and Affiliations

  1. The Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

    Cara C. Tigue, Karen A. Fitzner, Motasem Alkhatib, Eric Schmid & Charles L. Bennett

  2. The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

    Cara C. Tigue, Karen A. Fitzner, Motasem Alkhatib, Eric Schmid & Charles L. Bennett

  3. VA Center for Management of Complex Chronic Care, Jesse Brown VA Medical Center, Chicago, IL, USA

    Cara C. Tigue & Charles L. Bennett

  4. Northwestern University, 303 E. Chicago Avenue, Olson Pavilion, Suite 8250, Chicago, IL, 60611, USA

    Charles L. Bennett

Authors
  1. Cara C. Tigue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen A. Fitzner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Motasem Alkhatib
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Charles L. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles L. Bennett.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tigue, C.C., Fitzner, K.A., Alkhatib, M. et al. The value of innovation: the economics of targeted drugs for cancer. Targ Oncol 2, 113–119 (2007). https://doi.org/10.1007/s11523-007-0043-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-007-0043-8

Keywords

Search

Navigation